Differences in Reporting of Analyses in Internal Company Documents Versus Published Trial Reports: Comparisons in Industry-Sponsored Trials in Off-Label Uses of Gabapentin

Using documents obtained through litigation, S. Swaroop Vedula and colleagues compared internal company documents regarding industry-sponsored trials of off-label uses of gabapentin with the published trial reports and find discrepancies in reporting of analyses.

[1]  Matthias Briel,et al.  Inconsistent Definitions for Intention-To-Treat in Relation to Missing Outcome Data: Systematic Review of the Methods Literature , 2012, PloS one.

[2]  R. Little,et al.  The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.

[3]  J. Drazen.  Transparency for clinical trials--the TEST Act. , 2012, The New England journal of medicine.

[4]  S. Vedula,et al.  Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigation , 2012, Trials.

[5]  Kay Dickersin,et al.  The evolution of trial registries and their use to assess the clinical trial enterprise. , 2012, JAMA.

[6]  Tom Jefferson,et al.  The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience , 2012, PLoS medicine.

[7]  A. Kesselheim,et al.  False Claims Act prosecution did not deter off-label drug use in the case of neurontin. , 2011, Health affairs.

[8]  Andreas Pott.  EMA’s response to articles , 2011, BMJ : British Medical Journal.

[9]  Nicholas C. Ide,et al.  The ClinicalTrials.gov results database--update and key issues. , 2011, The New England journal of medicine.

[10]  Maria Laura Luchetta,et al.  Modified versus standard intention-to-treat reporting: Are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study , 2011, Trials.

[11]  Iosief Abraha,et al.  Modified intention to treat reporting in randomised controlled trials: systematic review , 2010, BMJ : British Medical Journal.

[12]  D. Moher,et al.  CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.

[13]  Kay Dickersin,et al.  Outcome reporting in industry-sponsored trials of gabapentin for off-label use. , 2009, The New England journal of medicine.

[14]  Douglas G Altman,et al.  Missing outcomes in randomized trials: addressing the dilemma , 2009, Open medicine : a peer-reviewed, independent, open-access journal.

[15]  An Unbiased Scientific Record Should Be Everyone's Agenda , 2009, PLoS medicine.

[16]  Douglas G Altman,et al.  Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols , 2008, BMJ : British Medical Journal.

[17]  An-Wen Chan,et al.  Bias, Spin, and Misreporting: Time for Full Access to Trial Protocols and Results , 2008, PLoS medicine.

[18]  Lisa Bero,et al.  Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation , 2008, PLoS medicine.

[19]  E. Kalso,et al.  Gabapentin in traumatic nerve injury pain: A randomized, double-blind, placebo-controlled, cross-over, multi-center study , 2008, PAIN.

[20]  You Suning.  Sixth International Congress on Peer Review and Biomedical Publication , 2008, BMJ : British Medical Journal.

[21]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[22]  Aaron S Kesselheim,et al.  Confidentiality laws and secrecy in medical research: improving public access to data on drug safety. , 2007, Health affairs.

[23]  E. Vieta,et al.  A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. , 2006, The Journal of clinical psychiatry.

[24]  E. Turner,et al.  A Taxpayer-Funded Clinical Trials Registry and Results Database , 2004, PLoS medicine.

[25]  M. Maltoni,et al.  Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. Parsons,et al.  Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response , 2004 .

[27]  McCleane Gj.  Comment on: Serpell et al., gabapentin in neuropathic pain syndromes: a randomised double-blind, placebo controlled trial (Pain 2002; 99: 557-66). , 2003 .

[28]  R. Kruse,et al.  Intention-to-treat analysis: who is in? Who is out? , 2002, The Journal of family practice.

[29]  M. Serpell.  Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial , 2002, Pain.

[30]  T. Ketter,et al.  Gabapentin augmentation therapy in bipolar depression. , 2002, Bipolar disorders.

[31]  G H Guyatt,et al.  Intention-to-treat principle. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[32]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.

[33]  D. Moher,et al.  Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. , 2001, JAMA.

[34]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[35]  N. Ramadan,et al.  Efficacy of Gabapentin in Migraine Prophylaxis , 2001, Headache.

[36]  P. Glemain.  L'intention de traiter , 2000 .

[37]  P. Mazzarello,et al.  Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. , 2000, Journal of pain and symptom management.

[38]  P. Suppes,et al.  Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. , 2000, Bipolar disorders.

[39]  M. Martínez-González,et al.  Intention to treat analysis is related to methodological quality , 2000, BMJ : British Medical Journal.

[40]  S. Hollis,et al.  What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.

[41]  W. Rand,et al.  Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial , 1999, Journal of neurology, neurosurgery, and psychiatry.

[42]  A. Beydoun,et al.  Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: a Randomized Controlled Trial , 1999 .

[43]  C. Baumgartner,et al.  Preliminary Results Of A Double Blind Study With The New Migraine Prophylactic Drug Gabapentin , 1987 .

[44]  Hill Ab,et al.  The clinical trial. , 1952 .

[45]  R. Guy,et al.  International Conference on Harmonisation , 2014 .

[46]  M. Ünlü.  It is Time: Why the FDA Should Start Disclosing Drug Trial Data , 2010 .

[47]  Miroslav Backonja,et al.  Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. , 2003, Clinical therapeutics.

[48]  International conference on harmonisation; guidance on statistical principles for clinical trials; availability--FDA. Notice. , 1998, Federal register.

[49]  J. Gillespie,et al.  Findings of fact and conclusions of law , 1978 .